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Inﬂuenza virus represents a serious threat to public health. The lack of effective drugs against ﬂu
prompted researchers to identify more promising viral target. In this respect hemagglutinin (HA) can
represent an interesting option because of its pivotal role in the infection process.
With this aim we collected a small library of commercially available compounds starting from a large
database and performing a diversity-based selection to reduce the number of screened compounds
avoiding structural redundancy of the library. Selected compounds were tested for their
hemagglutination-inhibiting (HI) ability against two different A/H1N1 viral strains (one of which is
oseltamivir sensitive), and 17 of them showed the ability to interact with HA. Five drug-like molecules, in
particular, were able to impair hemagglutination of both A/H1N1 viral strains under study and to inhibit
cytopathic effect and hemolysis at sub-micromolar level.
& 2015 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza A viruses cause acute respiratory infection and can
represent a severe threat for aged and high-risk people. Moreover,
the recent emergence of highly pathogenic avian and swine ﬂu has
become a global issue to humans.
To date, the treatment of inﬂuenza A infection relies on vacci-
nation and four approved anti-inﬂuenza drugs that hit two viral
targets: M2 ion channel (amantadine and rimantadine) and
neuraminidase (oseltamivir and zanamivir). Unfortunately, side
effects and the emergence of drug-resistant strains have been
reported for the above approved drug classes, limiting their
effectiveness (Cheng et al., 2010; Deyde et al., 2007; Hay et al.,
2008; Gubareva et al., 2009). Potential novel targets are being
explored for the development of new weapons against ﬂu (Das
et al., 2010). Among them, hemagglutinin (HA) deserves a special
attention because of its pivotal role in the infection process.
HA is a glycoprotein expressed on the viral surface along with
neuraminidase (NA). It is responsible for the attachment of the
viral particle to the host cell through cell surface-sialic acid
receptor (Hartshorn et al., 1995). At a later stage it is able to carry
out a pH-dependent conformational rearrangement necessary to
fuse the viral membrane with the endosome producing the
infection (Skehel et al., 1982).: þ39 0649902137.18 subtypes of inﬂuenza A HAs have been classiﬁed so far (Tong
et al., 2012, 2013), that can be divided in two major groups: group
1 (with two clades including H3) and group 2 (with 3 clades
including H1) (Russell et al., 2008).
From a structural point of view, HA is a homotrimer with a
mushroom-like shape (Fig. 1).
During the maturation process each monomer is cleaved in two
subunits: HA1 and HA2 connected through disulﬁde bridges. The
HA1 chain constitutes mainly the globular head of the HA and
includes the receptor binding site (Wilson et al., 1981) that is
responsible for sialic acid recognition (Skehel and Wiley, 2002)
and undergoes frequent mutations to escape antibody protection
(antigenic drift). The HA2 chain occupies the stem region and
contains the machinery able to produce a structural modiﬁcation
at low pH, thereby the hydrophobic fusion peptide is exposed and
promotes the fusion with the endosome membrane, essential to
virion internalization. Because of this functional role the HA2
sequence is very conserved among the HA subtypes. Targeting this
region of the HA may produce broad spectrum agents less sub-
jected to the onset of resistances. Indeed, human monoclonal
antibodies binding to the stalk region of HA have been recently
reported with broad-spectrum activity (Sui et al., 2009; Ekiert
et al., 2009).
Several small molecules binding the HA have been disclosed so
far (Yang et al., 2013; Vanderlinden and Naesens, 2014; Li et al.,
2015). Among the known ligands, a few have a widespread
activity, as most of them are subtype-speciﬁc (Motohashi et al.,
2013). Moreover, the binding site of these ligands on the HA
Fig. 1. Cartoon representation of the HA trimeric structure. Each monomer has a
different color; the HA2 subunit is represented in pale color, the fusion peptide is
depicted in black, the receptor binding site on the upper part of HA is indicated.
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1993), a small molecule active toward H3 subtypes that has been
co-crystallized with the hemagglutinin (Russell et al., 2008). Its
binding site may not be conserved in other HA subtypes therefore
this information could not be exploited for the design of new
ligands based on the structure of the receptor (structure-based
drug design). On the other hand, ligand-based approaches, that
uses the structural information of the known active molecules
usually identiﬁes compounds similar to the template molecules
(Scior et al., 2012).
It is well known that to ﬁnd new scaffold hits the random
screening can be considered the best route even with low hit rate.
To reach this objective a compound library ideally covering the
whole chemical space (or better the “drug space”) should be
explored, submitting to experimental testing a huge amount of
compounds, such in a HTS campaign, with high costs and long
times. In this respect, chemoinformatics analysis of a virtual
library can help to reduce the number of molecules to be tested,
eliminating redundancy and selecting a small representative sub-
set of the starting library (Rishton, 2008).
In the present work a small library of diverse compounds-
selected from a large molecule dataset-was screened evaluating
their ability to block the hemagglutination caused by the virus.
Two different A/H1N1 viral strains were used for this study (A/
RomaISS/02/08 H1N1 oseltamivir-sensitive virus, A/Parma/24/09
H1N1 oseltamivir-resistant virus). A good number of hits resulted
from this test, some of them being able to block both A/H1N1 viral
strains.Results
Diverse library selection
The diversity-driven selection protocol was aimed to obtain a
representative subset of the starting compound collection. The
selection was performed in silico through chemoinformatics ana-
lysis of the virtual library.For the screening purposes we downloaded almost 950,000
commercially available compounds from the Zinc database (http://
zinc.docking.org/, Irwin and Shoichet, 2005).
The in silico exploration of the chemical space was conﬁned to a
smaller region occupied by “drug-like” compounds. This region is
deﬁned by physicochemical properties accounting for the drug-
likeness of compounds, i.e. physical properties and chemical
functionalities consistent with the majority of known drugs and
correlated with an adequate bioavailability (Lipinski et al., 2001;
Veber et al., 2002; Walters and Murcko, 2002). This methodology
is aimed to apply ADME (absorption, distribution, metabolism, and
excretion) considerations early in the drug discovery process to
avoid costly late stage preclinical and clinical failures (Egan et al.,
2000; Knox et al., 2005).
Moreover, undesired structures, containing reactive or toxic
functional groups, were removed form the collection. The ﬁltering
procedure afforded a ﬁnal collection of 495,000 molecules that
were then used for the diversity-based selection.
The chemical similarity/diversity of molecules can be expressed
as a number that quantiﬁes the “distance” between two com-
pounds. The number representing each compound can vary
depending on the structural properties (descriptors) calculated to
represent the molecules (Olah et al., 2004). In our approach we
described compounds through their ﬁngerprints: a widely used 1D
representation of a chemical structure allowing for the che-
moinformatics analysis of a large library (Willett, 2006). In our
study the 2D ﬁngerprints were calculated and used to cluster all
structures, applying the widely used Tanimoto similarity metric.
The selection of the most representative molecule from each group
afforded a ﬁnal non-redundant library of compounds. On the basis
of our screening capabilities, a ﬁnal subset of 105 readily available
compounds have been purchased and submitted to HI assays.
Structures of all tested compounds are reported in Electronic
Supplementary material (Fig. S1).
Interaction of compounds with viral hemagglutinin and neutraliza-
tion of Inﬂuenza virus
Selected compounds were tested in HI assay on two A/H1N1
viral subtypes (one sensitive and one resistant to oseltamivir) in
order to check the inﬂuence of the NA mutation on the HA activity.
As a matter of fact, both proteins are expressed on the virion
surface and changes in NA sialidase conformation likely inﬂuence
HA receptor-binding activity.
HI screening afforded 17 compounds with sub-micromolar
activity over 105 assayed. The chemical structure of active com-
pounds and results of HI activity are reported in Tables 1–3.
Among the compounds showing inhibiting effect, four were
selective for A/Roma-ISS/2/08 (Table 2), eight were selective for
A/Parma/24/09 (Table 3) and ﬁve were active on both H1N1 strains
(Table 1). We also examined whether, and to what extent, these
ﬁve compounds were able to neutralize virus infection. Cytotoxi-
city studies demonstrated that identiﬁed compounds did not
induce signiﬁcant cytotoxicity in MDCK cells until 64 μM. Thus,
subsequent neutralization studies were performed with com-
pound concentrations ranging from 0 to 64 μM. All compounds
were able to prevent Inﬂuenza virus infection at concentration
ranging from 250 to 500 nM conﬁrming HI results (data not
shown).
Pharmacophore analysis
Active compounds in HI assays share similar structural fea-
tures: two or three aromatic or heterocyclic groups spaced by an
amide, amine or sulfonamide function. However, the simple ana-
lysis of the chemical structures does not readily provide an
Table 1
HI titers of compounds interacting with both strains.
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active compound common pharmacophore models were gener-
ated in order to elicit the main features responsible for the activity
toward the two A/H1N1 strains.
Active compounds were aligned with Phase attempting to ﬁnd
a common pharmacophore hypothesis separately for compounds
actives toward oseltamivir-resistant (A/Parma) and those active
toward oseltamivir sensitive (A/Roma) strain.
The two models were obtained using Phase (Schrödinger, 2012)
and aligning all compounds active toward the same viral strain.
Resulting hypotheses are composed by the same combination offeatures (ADHRR; Acceptor, Donor, Hydrophobic and two aromatic
Rings), but are differently arranged in the 3D space (Fig. 2).Anti-inﬂuenza activity
Inhibition of infection and hemolysis assays conﬁrm the
activity of broad-spectrum compounds toward both subtypes
(Table 4).
The ﬁrst assay assesses the ability of the compounds to protect
cells against viral infection. Compounds 5 and 6 showed the best
Table 2
HI titers of compounds interacting with oseltamivir-sensitive strain (A/RomaISS/02/08 H1N1).
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A/Roma, respectively, and a good selectivity proﬁle.Time course assay
The antiviral mechanism of selected ﬁve compounds was
examined by a time course assay (time of drug addition, Fig. 3) in a
single infectious cycle using both Inﬂuenza A H1N1 strains. Results
from our experiments showed that all the compounds totally
prevented viral infection when present throughout the infection
and, in particular, their antiviral effect was exerted at the early
stage of virus infection (0–2 h). Moreover, the temporal kinetic of
the inhibitory activity of all compounds was quite similar. These
results suggest that these molecules could affect Inﬂuenza virus
infection by acting not only on viral binding to host cells but also
on the fusion step required for the viral uncoating.Combination treatment of selected compounds and oseltamivir
Finally, the potential additive or synergistic effect with oselta-
mivir of the ﬁve most promising molecules (compounds 3–7 active
on both H1N1 strains) was performed to gain deeper insight into
the mode of their antiviral action.
To this aim a combination treatment of these molecules and
oseltamivir was carried out on the oseltamivir-sensitive viral
strain (A/RomaISS/02/08 H1N1). Synergistic effect was observed
only when virus-infected cells were incubated in the presence of
compound 6 (from 0.97 nM to 500 nM) and oseltamivir (from
117 nM to 15 μM) (Fig. 4).
A quantitative measure of the total synergy of a drug combi-
nation can be expressed in terms of synergy volumes (Prichard
et al., 1992). As synergy volume values 4100 μM2% are considered
synergic, compound 6, with a synergy volume of 305.23 μM2% in
combination with oseltamivir, displayed marked synergistic inhi-
bition of Inﬂuenza virus infection. The synergy produced by the
Table 3
HI titers of compounds interacting with oseltamivir-resistant strain (A/Parma/24/09 H1N1).
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Fig. 2. Representation of the pharmacophore hypotheses obtained for compounds active towards A/Parma (A) and A/Roma (B). Pharmacophore features are represented:
hydrophobic as a green sphere, aromatic as an orange ring, H-bond donor as a cyan vector and the acceptor as a red vector. The reference compound for each pharmacophore
hypothesis is shown as well in stick (compound 16 in (A) and 4 in (B)). The program Phase, in fact, automatically selects the reference molecule to whom pharmacophore all
other ligands are aligned.
Table 4
Anti-inﬂuenza activity evaluated using cell protection assay in MDCK cells infected with Inﬂuenza virus.
Compound nCC50 (μM) °EC50 (nM) ^SI #IC50 (nM)
A/Roma A/Parma A/Roma A/Parma A/Roma A/Parma
3 300 500þ/0.01 125þ/0.01 6.102 2.4.103 254þ/0.001 220.7þ/0.002
po0.01 po0.01
4 200 200þ/0.09 250þ/0.07 1.103 8.102 241.5þ/0.003 229.9þ/0.001
po0.01 po0.01
5 450 150þ/0.07 62þ/0.02 3.103 7.25.103 244þ/0.002 230.7þ/0.001
po0.01 po0.01
6 250 62þ/0.07 125þ/0.03 4.103 2.103 242.4þ/0.002 240þ/0.003
po0.01 po0.01
7 100 800þ/0.06 250þ/0.01 1.25.102 4.102 277.7þ/0.002 333.3þ/0.001
po0.01 po0.01
nCC50 cytotoxic concentration 50%, °EC50 effective infection inhibiting concentration 50%, ^SI (selectivity index)¼CC50/EC50, #IC50 hemolysis inhibiting concentration 50%.
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at the 95% conﬁdence level (data not shown).Discussion
HA represents an attractive target to ﬁnd new anti-Inﬂuenza
agents, because of its important role in host cell attachment and
fusion process (Hartshorn et al., 1995; Skehel et al., 1982).
Several small molecules have been identiﬁed so far that are
able to interfere with the HA functions. They can hinder one or
both the functions played by HA: some of them bind the receptor
binding site competing with sialic acid such as triterpenoids (Yu
et al., 2014) and sialic acid mimetic peptides (Matsubara et al.,
2010). The majority of identiﬁed compounds, however, block the
fusion process promoted by HA preventing the conformational
rearrangement of HA at low pH. Among these molecules we can
mention arbidol that has been commercialized in Russia and China
(Bodian et al., 1993; Boriskin et al., 2008), stachyﬂin derivatives
(Yoshimoto et al., 2000; Motohashi et al., 2013), CL-61917 and its
analogues (Plotch et al., 1999), polyphenols (Yang et al., 2014),
BMY 27709 (Luo et al., 1997) and many others that have been
recently reviewed (Yang et al., 2013; Vanderlinden and Naesens,
2014; Li et al., 2015).
The claimed mechanism of action concerns the interaction with
the HA2 chain or, better, the stem region that, because of its role in
the fusion machinery, is more conserved among viral strains and
should be less prone to mutations. However, most of them are
subtype selective and the mechanism of action has not beenexactly clariﬁed, while experimental binding mode has been
assessed just for TBHQ, a simple ligand blocking fusion of H3
Inﬂuenza strains.
The rational design has been applied to identify TBHQ (dock-
ing) (Hoffman et al., 1997) and ciclopentane derivatives through
ligand-similarity search (Tang et al., 2010), while most of HA
inhibitors have been selected through HTS: in a recent work Basu
and co-workers reported the results of a HTS screening that
identiﬁed 36 primary hits over 106,000 tested compounds with a
hit rate of 0.035% (Basu et al., 2014). In this context, the present
study represents an example of an effective approach to identify
active compounds avoiding the screening of a large number of
compounds.
In our work we exploited the chemoinformatics analysis of a
larger library to select a small diverse library screened in HI assays
to identify new potential antiviral compounds. Chemoinformatics
is a well-established tool in the drug discovery process, able to
easily manage large molecule collections (Zhou, 2011). In this case
its use allowed to strongly reduce the number of assayed com-
pounds with a much smaller effort, in terms of costs and time, for
the biological screening. In fact, we identiﬁed 17 active compounds
over 105 tested molecules and 5 of them were actives on both
H1N1 strains with a ﬁnal hit rate of 5%.
The activity showed in the HI assays relies on the direct com-
petition of the small molecules with the sialic acid (SA) on the host
cell. The haemagglutination, in fact, is due to the recognition
between the SA and the receptor binding site on the upper part of
the HA (HA1 subunit, see Fig. 1). Therefore, our molecules should
be able to bind this site of HA competing with the natural binder
Fig. 3. Addition time effect of compounds on Inﬂuenza virus A/Roma ISS/02/08
H1N1 (A), and Inﬂuenza virus A/Parma/24/09 H1N1 (B) infection. After adsorption
step (1 h at 4 °C; time zero), incubation temperature was shifted to 37 °C and EC50
concentrations of each compound were added to infected cells at different time
intervals after time zero. After 6 h incubation at 37 °C, viral antigen synthesis was
measured by immunoﬂuorescence. Data represents the means of at least three
independent experiments.
Fig. 4. Three-dimensional plots showing the interaction of compound 6 (nM) and
oseltamivir (μM) on the replication of Inﬂuenza virus. Synergy was analyzed by the
three-dimensional model of Prichard and Shipman, using the MacSynergy II soft-
ware at 95% conﬁdence limits.
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Actually, the displacement of sialic acid from its binding site can be
carried out also by weak binders as it binds HA in the millimolar
range (Takemoto et al., 1996).
Moreover, the selectivity observed in the HI assay for the two
viral strains could be due to the mutated residues. The HA
sequences of the two H1N1 strains considered in this work, are
very conserved, with just four different residues surrounding the
receptor binding site in the HA1 chain (the alignment of the two
HA sequences is reported in Supplementary material, Fig. S2). The
obtained pharmacophore hypotheses highlighted that active
compounds have the same features, differing for the 3D space
arrangement, thus suggesting that these compounds may bind the
same site with different conformations. We could hypothesize that
compounds active toward both strains are able to satisfy the
conformational requirements for both HAs.
Neutralization assay showed that the ﬁve compounds inter-
acting with both strains were also able to prevent virus–cell
interaction. As a matter of fact, pretreatment of virus samples with
these molecules provided 100% protection against both viral
strains in vitro. These results support the hypothesis that small
identiﬁed molecules could be able to prevent infection by a direct
interaction with HA1 subunit.
The analysis of structural features of identiﬁed compounds
(two aromatic portions linked by an amine/amide or sulfonamide
function) put in evidence that they share common characteristics
with already disclosed HA ligands such as 1e (Zhu et al., 2012) and
MBX2546 (Basu et al., 2014), that have been demonstrated to blockthe HA mediated fusion. Indeed, the time course assay carried out
for the ﬁve active compounds shows that they act in the early
stage of the infection process.
Therefore, our results suggest that these molecules should be
able to interact with the receptor binding site on the HA1 subunit,
competing with the sialic acid, and, at the same time, to interfere
with the HA2-mediated membrane fusion. In this respect, in is
worth mentioning that the compound MBX2546 shares with our
molecules a very similar activity proﬁle: it is able to block both the
hemagglutination and the fusion process and its binding the HA
stem has been assessed by NMR studies. The already mentioned
structural similarity with our ligands could suggest they interact
similarly with HA.
Our results on double combination of small molecules and
oseltamivir demonstrate that only compound 6 exhibits marked
synergy with oseltamivir (synergy volume 305.23 μM2%). This
represents an interesting ﬁnding as values over 100 μM2% indicate
strong synergy and are considered probably important in vivo
(Prichard and Shipman, 1990). The body of published work indi-
cates that the synergy of double combinations varied and can be
dependent on the drug combination, drug dose, experimental
design and virus strain (Nguyen et al., 2009). For instance the
combination of rimantadine and ribavirin was found synergistic
against inﬂuenza H1N1 and H3N2 strains in one study (Hayden
et al., 1980) but was found to be additive against different H1N1
and H3N2 strains in another investigation (Madren et al., 1995).
Moreover, it has been reported that oseltamivir in combination
with ribavirin was antagonistic, additive, or synergistic in mouse
models, depending on the virus strain and/or the dose of the drugs
(Govorkova et al., 2004; Smee et al., 2006). So, the variability in
synergy for double compound combinations reported in the lit-
erature, due to the speciﬁc drugs in the combinations or to the
virus strain, is consistent with the in vitro data we present here.
As Inﬂuenza virus productive infection requires a balance
between the HA-mediated binding and entry process (early steps)
and NA-mediated egress process (late step), the observed synergy
is likely due to the simultaneous inhibition of HA-mediated
activities by compound 6 (early steps) and NA-mediated egress
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of this small molecule inhibitor as potential anti-Inﬂuenza ther-
apeutic agent, either individually or in combination with current
anti-viral treatments, appears promising.
In conclusion we have identiﬁed ﬁve novel H1N1 inﬂuenza A
virus inhibitors. The activity proﬁle along with their drug-like
properties makes them an optimal starting point for the devel-
opment of a therapeutic agent against ﬂu.
In particular, one of these molecules showed attractive prop-
erties deserving further investigation about the mechanism lead-
ing to its high synergy with oseltamivir.Materials and methods
Diverse library selection
2D structure data ﬁles (.sdf ﬁles) of commercially available
compounds from Specs, Enamine and Asinex suppliers were
downloaded from the ZINC database (Irwin and Shoichet, 2005;
http://zinc.docking.org/). A total of almost 950,000 compounds
were imported into CANVAS (Schrödinger, 2012; Sastry et al.,
2010; Duan et al., 2010), an interface able to apply several che-
moinformatics techniques. The following molecular properties
were calculated for each compound: MW, number of rotatable
bonds and H-bond donors and acceptors, PSA, AlogP, molecular
polarizability and molecular refractivity. In order to obtain a col-
lection of lead-like compounds the initial library was ﬁltered
applying the following parameter cut-off: MWo500 and
4¼200; HBD40 and o¼5; HBAo¼10; AlogP4¼2 and
o¼5; RB4¼2 and o¼8; MR4¼40 and o¼130; PSAo¼120.
Resulting compounds were ﬁltered also to eliminate all reactive
and undesired functional group, applying a REOS ﬁlter available in
Canvas (Walters et al., 1998).
Binary 2D ﬁngerprints were generated for all resulting mole-
cules (495,000). The hashed linear ﬁngerprints were calculated
using the Daylight invariant atom types speciﬁcation and distin-
guishing bonds by bond order. A 32-bit precision was applied,
ﬁltering bits by ON/OFF frequencies. Generated ﬁngerprints were
used to perform a clustering of all structures in order to collect
most similar molecules in the same group. To this aim the Leader-
follower clustering method was used, applying the Tanimoto
similarity metric and a cluster radius of 0.5. Most representative
compounds of each cluster were selected. The list of purchased
compounds is reported as Supplementary material.
Pharmacophore model generation
Non-racemic compounds showing activity in the HI assays
were submitted to the Develop Common Pharmacophore module
in Phase (Schrödinger, 2012), Active compounds protonation state
at physiological pH was calculated using Epik (Schrödinger, 2012).
The conformational model for each compound has been generated
using ConfGen and performing a thorough research. Five-sites
hypotheses were generated applying the default parameters.
Virus strains
The following Brisbane-like Inﬂuenza A virus strains were
used: A/RomaISS/02/08 H1N1 oseltamivir-sensitive virus and A/
Parma/24/09 H1N1 oseltamivir-resistant virus. Virus titers were
determined by a hemagglutination and/or plaque assays according
to the standard procedures (Gaush and Smith, 1968; Rimmelzwaan
et al., 1998).Cells
Madin-Darby canine kidney (MDCK, ATCC, CRL-2936) cells
were grown at 37 °C in minimal essential medium (MEM, Invi-
trogen, Paisley, UK) containing 1.2 g/l NaHCO3 and supplemented
with 10% inactivated fetal calf serum (FCS, Invitrogen, Paisley, UK),
2 mM glutamine, nonessential amino acids, penicillin (100 IU/ml)
and streptomycin (100 μg/ml).
Compounds
Small molecules identiﬁed in the computational screening of
ZINC database were purchased from Enamine Ltd. as dry powders.
Compound purity, assessed by NMR and LC-MS, is higher than
92%. Chiral compounds are provided as racemic mixture. Com-
pounds were dissolved in dimethylsulfoxide (DMSO, Sigma, Che-
mical Company, St.Louis, MO, USA) at 2 mmol/L and stored at
20 °C in amber glass vials.
Oseltamivir carboxylic acid, the active form of oseltamivir
((3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclo-
hexene-1-carboxylicacid) (Roche) was dissolved in H2O at
2.4 mmol/L and stored at 20 °C.
Cytotoxicity assay
Two-fold serial dilutions of each compound and DMSO or H2O
in culture medium were incubated at 37 °C with conﬂuent MDCK
cells grown in 96-well tissue culture microplates (Nalge Nunc
Europe Ltd, Neerijse, Belgium). After 24 and 48 h, the cytoxicity
was measured by the neutral red (NR) uptake assay. Brieﬂy, the
cells were rinsed in PBS, and NR incorporated in viable cells was
extracted with a solution of 50% (v/v) ethanol and 1% (v/v) acetic
acid for 10 min before measuring optical density at 550 nm using
an ELISA plate reader (PerkinElmer Italia, Monza).
The ODs from identical wells were averaged, and compound
cytotoxicity was expressed as the minimum cytotoxic concentra-
tion (MCC), i.e. the concentration producing minimal changes in
cell morphology, or the CC50 value, i.e. the concentration causing
50% reduction in cell viability by NR assay. The cytotoxicity was
computed by comparison to the average OD of wells containing
compounds with the average OD of wells containing DMSO, H2O
and culture medium alone.
Hemagglutination inhibition assay (HI)
Virus in PBS was incubated for 1 h at 4 °C with serial dilutions
of compounds in PBS. An equal volume of 0.5% turkey erythrocytes
was then added and allowed to agglutinate. Titers were expressed
as the reciprocal of the compound dilutions giving 50% hemag-
glutination of erythrocytes by four virus agglutinating units.
Neutralization assay
Neutralization was carried out by incubating serial twofold
compound dilutions, starting from 1 mM, in culture medium with
equal volumes of virus suspension containing 1.106 p.f.u. for 1 h at
4 °C. MDCK cells were seeded on 96-well tissue culture micro-
plates (Nalge Nunc Europe Ltd., Neerijse, Belgium) at the con-
centration of 20,000 cells/well and allowed to grow for 24 h at
37 °C in 5% CO2. After this time, cells were incubated for 1 h at
37 °C with 100 μl/well of the virus-protein mixtures. Infection was
carried out in quadruplicate at a multiplicity of infection of 10
plaque forming units (p.f.u.)/cell. After viral adsorption, cells were
rinsed thoroughly and incubated at 37 °C for 48 h. The cytopathic
effect (c.p.e.) induced by infection was measured by the neutral
red uptake assay (Marchetti et al., 2004), and results were
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untreated control cultures. EC50 was deﬁned as the compound
concentration that generates 50% of the maximal protection. Per-
centage of protection was calculated by the equation (A550
compound-virus-A550 virus)/(A550 mock infected cells-A550 virus)
x100%. The data were expressed as the EC50 relative to the value
observed in the absence of compound.
Hemolysis inhibition assay
Hemolysis inhibition assays were modiﬁed from those descri-
bed previously (Bodian et al., 1993). Brieﬂy, 100 μl (about 6 μg of
protein) of puriﬁed virus were incubated at 37 °C for 1 h with an
equal volume of PBS containing various concentrations of com-
pounds. Then, 200 μl of a 2.0% solution of turkey red blood cells
(RBCs) in PBS were added to the reaction and further incubated at
37 °C for 10 min. The virus-bound turkey RBCs were pelleted by
centrifugation at 1600 rpm for 8 min and the RBC pellet was sus-
pended in 450 μl of low pH PBS buffer (pH 5.0 þ/0.05) con-
taining the corresponding concentration of compound. After
25 min incubation at 37 °C, the reaction was neutralized to pH 7.0
þ/0.2 by the addition of 1 N NaOH. Cell debris and unlysed cells
were pelleted down through centrifugation at 2000 rpm for 8 min.
Then 300 μl of supernatant were transferred to 96-well tissue
culture plate (Corning Incorporated, Corning, New York) for mea-
surement of optical density at a wavelength of 540 nm using a
multilabel plate reader (PerkinElmer Italia, Monza). Percentage of
protection was calculated by the equation (A540 compound-virus-
A540 virus)/(A540 PBS-A540 virus)x100%. The data were expressed
as the IC50 relative to the value observed in the absence of
compound.
Time course assay (time-of-addition)
The effect of small molecules on Inﬂuenza virus infection was
tested in a time-of-addition assay. For these experiments, infection
was synchronized by incubating the virus (m.o.i. 10) with the cells
for 1 h at 4 °C. After the attachment step, unbound virus was
removed by washing twice with medium and cells were incubated
for 6 h at 37 °C. The inhibiting activity of the ﬁve compounds was
assessed by different experimental procedures: (i) the small
molecules were added to the infected cells after the temperature
shift and were present for the entire time of infection or, (ii) before
the addition of chemicals, infected cells were incubated for well-
deﬁned times. Inﬂuenza virus antigen synthesis was measured by
indirect immunoﬂuorescence.
Immunoﬂuorescence
MDCK infected cells were washed in PBS, ﬁxed in acetone at
20 °C for 5 min, incubated with monoclonal anti-Inﬂuenza virus
antibodies (Immunological Sciences, Rome, Italy) for 45 min at
37 °C. After washing in PBS, viral antigen synthesis was estimated
by utilizing (FITC)-conjugated anti-mouse gammaglobulin anti-
bodies (Sigma Chemical Company) and an UV Leitz microscope.
Combination treatment of selected compounds and oseltamivir
The combination treatment of selected compounds and osel-
tamivir was performed to demonstrate additive or synergistic
effects on the replication of the oseltamivir sensitive Inﬂuenza
virus strain A/RomaISS/2/08 H1N1. MDCK cells were infected at a
multiplicity of infection of 10 p.f.u./cell. After 1 h incubation at
37 °C the medium was replaced with mock-medium, or medium
containing oseltamivir (from 117 nM to 15 μM) compound 6 (from
0.97 nM to 500 nM) or combinations of both. The infected cellswere further incubated for 48 h, and virus replication was mea-
sured by Neutral Red assay. Drug–drug interactions were analyzed
by the three-dimensional model of Prichard and Shipman (1990),
using the MacSynergy ™II software (Prichard et al., 1992) at 95%
conﬁdence limits. Theoretical additive interactions were calculated
from the dose–response curve for each compound individually,
and the calculated additive surface was subtracted from the
experimentally determined dose–response surface to give regions
of synergistic or antagonistic interactions. The resulting surface
appears as horizontal plane at 0% of synergy if the interactions of
two compounds are additive. Any peak above or below this plane
indicates synergy or antagonism, respectively.Acknowledgments
This work was supported by a Grant from Ministero della
Salute-Istituto Superiore di Sanita`-within the research Project:'-
Studio e sviluppo di nuovi farmaci antivirali contro infezioni da
virus inﬂuenzale A-H1N1’.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2015.11.024.References
Basu, A., Antanasijevic, A., Wang, M., Li, B., Mills, D.M., Ames, J.A., Nash, P.J.,
Williams, J.D., Peet, N.P., Moir, D.T., Prichard, M.N., Keith, K.A., Barnard, D.L.,
Caffrey, M., Rong, L., Bowlin, T.L., 2014. New small molecule entry inhibitors
targeting hemagglutinin-mediated inﬂuenza a virus fusion. J. Virol. 88,
1447–1460. http://dx.doi.org/10.1128/JVI.01225-13.
Bodian, D., Yamasaki, R., Buswell, R., Stearns, J., White, J., Kuntz, I., 1993. Inhibition
of the fusion-inducing conformational change of inﬂuenza hemagglutinin by
benzoquinones and hydroquinones. Biochemistry 32, 2967–2978. http://dx.doi.
org/10.1021/bi00063a007.
Boriskin, Y.S., Leneva, I.A., Pécheur, E.-I., Polyak, S.J., 2008. Arbidol: a broad-
spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 15,
997–1005. http://dx.doi.org/10.2174/092986708784049658.
Cheng, P.K.C., To, A.P.C., Leung, T.W.C., Leung, P.C.K., Lee, C.W.C., Lim, W.W.L., 2010.
Oseltamivir- and amantadine-resistant Inﬂuenza virus A (H1N1). Emerg. Infect.
Dis. 16, 155–156. http://dx.doi.org/10.3201/eid1601.091304.
Das, K., Aramini, J.M., Ma, L.-C., Krug, R.M., Arnold, E., 2010. Structures of inﬂuenza
A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 17,
530–538. http://dx.doi.org/10.1038/nsmb.1779.
Deyde, V.M., Xu, X., Bright, R.A., Shaw, M., Smith, C.B., Zhang, Y., Shu, Y., Gubareva,
L.V., Cox, N.J., Klimov, A.I., 2007. Surveillance of resistance to adamantanes
among inﬂuenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect.
Dis. 196, 249–257. http://dx.doi.org/10.1086/518936.
Duan, J., Dixon, S.L., Lowrie, J.F., Sherman, W., 2010. Analysis and comparison of 2D
ﬁngerprints: Insights into database screening performance using eight ﬁnger-
print methods. J. Mol. Graph. Model. 29, 157–170. http://dx.doi.org/10.1016/j.
jmgm.2010.05.008.
Egan, W., Merz, K., Baldwin, J., 2000. Prediction of drug absorption using multi-
variate statistics. J. Med. Chem. 43, 3867–3877. http://dx.doi.org/10.1021/
jm000292e.
Ekiert, D.C., Bhabha, G., Elsliger, M.-A., Friesen, R.H.E., Jongeneelen, M., Throsby, M.,
Goudsmit, J., Wilson, I.A., 2009. Antibody recognition of a highly conserved
Inﬂuenza virus epitope. Science 324, 246–251. http://dx.doi.org/10.1126/
science.1171491.
Gaush, C.R., Smith, T.F., 1968. Replication and plaque assay of Inﬂuenza virus in an
established line of canine kidney cells. Appl. Microbiol. 16, 588–594.
Govorkova, E.A., Fang, H.B., Tan, M., Webster, R.G., 2004. Neuraminidase inhibitor-
rimantadine combinations exert additive and synergistic antiinﬂuenza virus
effects in MDCK cells. Antimicrob. Agents Chemother. 48, 4855–4863. http://dx.
doi.org/10.1128/AAC.48.12.4855-4863.2004.
Gubareva, L., Okomo-Adhiambo, M., Deyde, V., Sheu, T.G., Garten, R., Smith, C.,
Barnes, J., Myrick, A., Hillman, M., Shaw, M., Bridges, C., Klimov, A., Cox, N., Cox
Centers for Disease Control and Prevention (CDC) Update: Drug. susceptibility
swine Orig. inﬂuenza A (H1N1) viruses, WR Morb. Mortal .Wkly. Rep, 58, 2009,
pp. 433–435.
M. Agamennone et al. / Virology 488 (2016) 249–258258Hartshorn, K., Liou, L., White, M., Kazhdan, M., Tauber, J., Tauber, A., 1995. Neu-
trophil deactivation by inﬂuenza A virus. Role of hemagglutinin binding to
speciﬁc sialic acid-bearing cellular proteins. J. Immunol. 154, 3952–3960.
Hay A., Collins, P.J., Russell R.J. Antivirals and resistance, In: H.D. Klenk, M. Matro-
sovich (Eds.), Proceedings of the Stech. J. Monographs in Virology, 27, 2008,
Avian Inﬂuenza, pp. 252–270.
Hayden, F.G., Douglas Jr., R.G., Simons, R., 1980. Enhancement of activity against
Inﬂuenza viruses by combinations of antiviral agents. Antimicrob. Agents
Chemother. 18, 536–541. http://dx.doi.org/10.1128/AAC.18.4.536.
Hoffman, L.R., Kuntz, I.D., White, J.M., 1997. Structure-based identiﬁcation of an
inducer of the low-pH conformational change in the Inﬂuenza virus hemag-
glutinin: irreversible inhibition of infectivity. J. Virol. 71, 8808–8820.
Irwin, J., Shoichet, B., 2005. ZINC-A free database of commercially available com-
pounds for virtual screening. J. Chem. Inf. Model. 45, 177–182. http://dx.doi.org/
10.1021/ci049714.
Knox, A., Meegan, M., Carta, G., Lloyd, D., 2005. Considerations in compound
database preparation-"hidden" impact on virtual screening results. J. Chem. Inf.
Model. 45, 1908–1919. http://dx.doi.org/10.1021/ci050185z.
Li, F., Ma, C., Wang, J., 2015. Inhibitors targeting the Inﬂuenza virus
hemagglutinin. Curr. Med. Chem. 22, 1361–1382. http://dx.doi.org/10.2174/
0929867322666150227153919.
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 2001. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv. Drug. Deliv. Rev. 46, 3–26. http://dx.
doi.org/10.1016/s0169-409x(00)00129-0.
Luo, G., Torri, A., Harte, W.E., Danetz, S., Cianci, C., Tiley, L., Day, S., Mullaney, D., Yu,
K.L., Ouellet, C., Dextraze, P., Meanwell, N., Colonno, R., Krystal, M., 1997.
Molecular mechanism underlying the action of a novel fusion inhibitor of
inﬂuenza A virus. J. Virol. 71, 4062–4070.
Madren, L.K., Shipman, C.J., Hayden, F.G., 1995. In vitro inhibitory effects of
combinations of anti-inﬂuenza agents. Antivir. Chem. Chemother. 6, 109–113.
http://dx.doi.org/10.1177/095632029500600205.
Marchetti, M., Trybala, E., Superti, F., Johansson, M., Bergstrom, T., 2004. Inhibition
of herpes simplex virus infection by lactoferrin is dependent on interference
with the virus binding to glycosaminoglycans. Virology 318, 405–413. http://dx.
doi.org/10.1016/j.virol.2003.09.029.
Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., Taki, T., Nagata, K.,
Okahata, Y., Sato, T., 2010. Sialic acid-mimic peptides as hemagglutinin inhibi-
tors for anti-inﬂuenza therapy. J. Med. Chem. 53, 4441–4449. http://dx.doi.org/
10.1021/jm1002183.
Motohashi, Y., Igarashi, M., Okamatsu, M., Noshi, T., Sakoda, Y., Yamamoto, N., Ito, K.,
Yoshida, R., Kida, H., 2013. Antiviral activity of stachyﬂin on inﬂuenza A viruses
of different hemagglutinin subtypes. Virol. J. 10, 118. http://dx.doi.org/10.1186/
1743-422X-10-118.
Nguyen, J.T., Hoopes, J.D., Smee, D.F., Prichard, M.N., Driebe, E.M., Engelthaler, D.M.,
Le, M.H., Keim, P.S., Spence, R.P., Went, G.T., 2009. Triple combination of osel-
tamivir, amantadine, and ribavirin displays synergistic activity against multiple
Inﬂuenza virus strains in vitro. Antimicrob. Agents Chemother. 53, 4115–4126.
http://dx.doi.org/10.1128/AAC.00476-09.
Olah, M.M., Bologa, C.G., Oprea, T.I., 2004. Strategies for compound selection.
Curr. Drug Discov. Technol. 1, 211–220. http://dx.doi.org/10.2174/
1570163043334965.
Plotch, S.J., O'Hara, B., Morin, J., Palant, O., LaRocque, J., Bloom, J.D., Lang, S.A.,
DiGrandi, M.J., Bradley, M., Nilakantan, R., Gluzman, Y., 1999. Inhibition of
inﬂuenza A virus replication by compounds interfering with the fusogenic
function of the viral hemagglutinin. J. Virol. 73, 140–151.
Prichard, M.N., Shipman Jr., C., 1990. A three-dimensional model to analyse drug–
drug interactions. Antivir. Res. 14, 181–206. http://dx.doi.org/10.1016/
0166-3542(90)90001-N.
Prichard, M.N., Aseltine, K.R., Shipman C. Jr. 1992 MacSynergy™ II (Version 1.0).
Users Manual University of Michigan, Ann Arbor.
Rimmelzwaan, G., Baars, M., Claas, E., Osterhaus, A., 1998. Comparison of RNA
hybridization, hemagglutination assay, titration of infectious virus and immu-
noﬂuorescence as methods for monitoring Inﬂuenza virus replication in vitro.
J. Virol. Methods 74, 57–66. http://dx.doi.org/10.1016/S0166-0934(98)00071-8.
Rishton, G.M., 2008. Molecular diversity in the context of leadlikeness: compound
properties that enable effective biochemical screening. Curr. Opin. Chem. Biol.
12, 340–351. http://dx.doi.org/10.1016/j.cbpa.2008.02.008.
Russell, R.J., Kerry, P.S., Stevens, D.J., Steinhauer, D.A., Martin, S.R., Gamblin, S.J.,
Skehel, J.J., 2008. Structure of inﬂuenza hemagglutinin in complex with an
inhibitor of membrane fusion. PNAS 105, 17736–17741. http://dx.doi.org/
10.1073/pnas.0807142105.
Sastry, M., Lowrie, J.F., Dixon, S.L., Sherman, W., 2010. Large-scale systematic ana-
lysis of 2D ﬁngerprint methods and parameters to improve virtual screening
enrichments. J. Chem. Inf. Model. 50, 771–784. http://dx.doi.org/10.1021/
ci100062n.
Schrödinger, 2012. Suite; Epik, version 2.3, Phase, version 3.4; Canvas, version 1.5.
LLC, New York, NY.Scior, T., Bender, A., Tresadern, G., Medina-Franco, J.L., Martinez-Mayorga, K.,
Langer, T., Cuanalo-Contreras, K., Agraﬁotis, D.K., 2012. Recognizing pitfalls in
virtual screening: a critical review. J. Chem. Inf. Model. 52, 867–881. http://dx.
doi.org/10.1021/ci200528d.
Skehel, J.J., Bayley, P.M., Brown, E.B., Martin, S.R., Waterﬁeld, M.D., White, J.M.,
Wilson, I.A., Wiley, D.C., 1982. Changes in the conformation of Inﬂuenza virus
hemagglutinin at the pH optimum of virus-mediated membrane fusion. PNAS
79, 968–972. http://dx.doi.org/10.1073/pnas.79.4.968.
Skehel, J., Wiley, D., 2002. Inﬂuenza haemagglutinin. Vaccine 20, S51–S54. http:
//dx.doi.org/10.1016/S0264-410X(02)00131-7.
Smee, D.F., Wong, M.H., Bailey, K.W., Sidwell, R.W., 2006. Activities of oseltamivir
and ribavirin used alone and in combination against infections in mice with
recent isolates of inﬂuenza A (H1N1) and B viruses. Antivir. Chem. Chemother.
17, 185–192. http://dx.doi.org/10.1177/095632020601700403.
Sui, J., Hwang, W.C., Perez, S., Wei, G., Aird, D., Chen, L.-m, Santelli, E., Stec, B.,
Cadwell, G., Ali, M., Wan, H., Murakami, A., Yammanuru, A., Han, T., Cox, N.J.,
Bankston, L.A., Donis, R.O., Liddington, R.C., Marasco, W.A., 2009. Structural and
functional bases for broad-spectrum neutralization of avian and human inﬂu-
enza A viruses. Nat. Struct. Mol. Biol. 16, 265–273. http://dx.doi.org/10.1038/
nsmb.1566.
Takemoto, D.K., Skehel, J.J., Wiley, D.C., 1996. A surface plasmon resonance assay for
the binding of Inﬂuenza virus hemagglutinin to its sialic acid receptor. Virology
217, 452–458. http://dx.doi.org/10.1006/viro.1996.0139.
Tang, G., Qiu, Z., Lin, X., Li, W., Zhu, L., Li, S., Li, H., Wang, L., Chen, L., Wu, J.Z., Yang,
W., 2010. Discovery of novel 1-phenyl-cycloalkane carbamides as potent and
selective inﬂuenza fusion inhibitors. Bioorg. Med. Chem. Lett. 20, 3507–3510.
http://dx.doi.org/10.1016/j.bmcl.2010.04.141.
Tong, S., Li, Y., Rivailler, P., Conrardy, C., Alvarez Castillo, D.A., Chen, L.-M., Recuenco,
S., Ellison, J.A., Davis, C.T., York, I.A., Turmelle, A.S., Moran, D., Rogers, S., Shi, M.,
Tao, Y., Weil, M.R., Tang, K., Rowe, L.A., Sammons, S., Xu, X., Frace, M., Lindblade,
K.A., Cox, N.J., Anderson, L.J., Rupprecht, C.E., Donis, R.O., 2012. A distinct lineage
of inﬂuenza A virus from bats. PNAS 109, 4269–4274. http://dx.doi.org/10.1073/
pnas.1116200109.
Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco,
S., Gomez, J., Chen, L.-M., Johnson, A., Tao, Y., Dreyfus, C., Yu, W., McBride, R.,
Carney, P.J., Gilbert, A.T., Chang, J., Guo, Z., Davis, C.T., Paulson, J.C., Stevens, J.,
Rupprecht, C.E., Holmes, E.C., Wilson, I.A., Donis, R.O., 2013. New World Bats
harbor diverse inﬂuenza A viruses. Plos. Pathog., 9. http://dx.doi.org/10.1371/
journal.ppat.1003657.
Vanderlinden, E., Naesens, L., 2014. Emerging antiviral strategies to interfere with
Inﬂuenza virus entry. Med. Res. Rev. 34 (301–339), 2014. http://dx.doi.org/
10.1002/med.21289.
Veber, D., Johnson, S., Cheng, H., Smith, B., Ward, K., Kopple, K., 2002. Molecular
properties that inﬂuence the oral bioavailability of drug candidates. J. Med.
Chem. 45, 2615–2623. http://dx.doi.org/10.1021/jm020017n.
Walters, W., Murcko, M., 2002. Prediction of drug-likeness. Adv. Drug. Deliv. Rev.
54, 255–271. http://dx.doi.org/10.1016/S0169-409X(02)00003-0.
Walters, W., Stahl, M., Murcko, M., 1998. Virtual screening-an overview. Drug
Discov. Today 3, 160–178. http://dx.doi.org/10.1016/S1359-6446(97)01163-X.
Willett, P., 2006. Similarity-based virtual screening using 2D ﬁngerprints. Drug
Discov. Today 11, 1046–1053. http://dx.doi.org/10.1016/j.drudis.2006.10.005.
Wilson, I.A., Skehel, J.J., Wiley, D.C., 1981. Structure of the haemagglutinin mem-
brane glycoprotein of Inﬂuenza virus at 3 A resolution. Nature 289, 366–373.
http://dx.doi.org/10.1038/289366a0.
Yang, J., Li, M., Shen, X., Liu, S., 2013. Inﬂuenza A virus entry inhibitors targeting the
hemagglutinin. Viruses 5, 352–373. http://dx.doi.org/10.3390/v5010352.
Yang, J., Yang, J.X., Zhang, F., Chen, G., Pan, W., Yu, R., Wu, S., Tien, P., 2014. Design,
synthesis and biological evaluation of small molecular polyphenols as entry
inhibitors against H(5)N(1). Bioorg. Med. Chem. Lett. 24, 2680–2684. http://dx.
doi.org/10.1016/j.bmcl.2014.04.057.
Yoshimoto, J., Yagi, S., Ono, J., Sugita, K., Hattori, N., Fujioka, T., Fujiwara, T., Sugi-
moto, H., Hashimoto, N., 2000. Development of anti-inﬂuenza drugs: II.
Improvement of oral and intranasal absorption and the anti-inﬂuenza activity
of stachyﬂin derivatives. J. Pharm. Pharmacol. 52, 1247–1255. http://dx.doi.org/
10.1211/0022357001777225.
Yu, M., Si, L., Wang, Y., Wu, Y., Yu, F., Jiao, P., Shi, Y., Wang, H., Xiao, S., Fu, G., Tian, K.,
Wang, Y., Guo, Z., Ye, X., Zhang, L., Zhou, D., 2014. Discovery of pentacyclic
triterpenoids as potential entry inhibitors of Inﬂuenza viruses. J. Med. Chem. 57,
10058–10071. http://dx.doi.org/10.1021/jm5014067.
Zhou, J.Z., 2011. Chemoinformatics and library design. Methods Mol. Biol. 685,
27–52. http://dx.doi.org/10.1007/978-1-60761-931-4_2.
Zhu, Z., Li, R., Xiao, G., Chen, Z., Yang, J., Zhu, Q., Liu, S., 2012. Design, synthesis and
structure–activity relationship of novel inhibitors against H5N1 hemagglutinin-
mediated membrane fusion. Eur. J. Med. Chem. 57, 211–216. http://dx.doi.org/
10.1016/j.ejmech.2012.08.041.
